iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that Mintu Turakhia, M.D. M.A.S. will join iRhythm in the new role of Chief Medical Officer and Chief Scientific Officer. Dr. Turakhia will join the executive leadership team to drive continued innovation, lead research and evidence generation, and enhance and augment the portfolio of clinical products and services.
Dr. Turakhia is an internationally recognized cardiac electrophysiologist and leader in digital health and heart rhythm care. He brings over 20 years of experience in patient care, outcomes research and trials, data science and artificial intelligence, medical device regulation, and the creation and commercialization of digital health products. In 2014, Dr. Turakhia performed the first-ever study of silent atrial fibrillation with the original Zio patch1, which helped to propel the field to perform large atrial fibrillation studies at scale, including the rhythm mSToPS Clinical Trial2. Dr. Turakhia is also a seasoned operator who has led the development of virtual care and remote patient monitoring software for clinical trials, academic research, and commercialized health care products.
“As healthcare continues to evolve at a rapid pace, we are very excited to add Dr. Turakhia to our executive team,” said Quentin Blackford, iRhythm President and CEO. “Mintu is a prolific scientist, respected clinician, and fast thinker whose work in heart rhythm and digital health is on the leading edge of healthcare innovation. Mintu’s forward-thinking approach to the future of medicine, including advanced technologies, artificial intelligence, and new models of care delivery will help iRhythm continue its evolution as a market leader in the digital healthcare space.”
Additionally, iRhythm’s Chief Clinical Officer Judy Lenane has announced her intention to retire from the company after nearly fourteen years of service. Ms. Lenane has been a highly valued member of the rhythm leadership team since joining the company in 2008.
“We would like to thank Judy for her significant contributions to iRhythm during her tenure. Her clinical, medical and strategic expertise has been crucial to getting our company to where we are today, and her unwavering patient focus will have an enduring influence on our company,” continued Mr. Blackford.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our filing made with the Securities and Exchange Commission on Form 10-K. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.
